Evoke Pharma Balance Sheet Health
Financial Health criteria checks 2/6
Evoke Pharma has a total shareholder equity of $-2.6M and total debt of $5.0M, which brings its debt-to-equity ratio to -193.8%. Its total assets and total liabilities are $7.1M and $9.6M respectively.
Key information
-193.8%
Debt to equity ratio
US$5.00m
Debt
Interest coverage ratio | n/a |
Cash | US$4.74m |
Equity | -US$2.58m |
Total liabilities | US$9.65m |
Total assets | US$7.07m |
Recent financial health updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Evoke Pharma shares surge on positive findings from Gimoti market research study
Jan 13Evoke Pharma EPS beats by $0.02
Nov 10Financial Position Analysis
Short Term Liabilities: EVOK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EVOK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVOK has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EVOK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVOK has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: EVOK is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.